Literature DB >> 3698176

The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro.

R Kanamaru, H Kakuta, T Sato, C Ishioka, A Wakui.   

Abstract

Addition of 5FU to the culture medium of mouse L-1210 cells resulted in inhibition of the maturation process of ribosomal RNA precursors in vitro. In the presence of 10(-6) M 5FU for 2 h, the 45S preribosomal RNA was processed to 32S preribosomal RNA, but 28S rRNA was not produced. The processing to 18S rRNA was intact at this drug concentration. Higher concentrations of 5FU for a longer incubation period affected the RNA processing more severely. At 10(-5) M of the drug for 24 h the processing to 28S rRNA and 32S preribosomal RNA. When the cells were labeled with 14C-UR for 2 h following 3H-5FU at 10(-6) M for 24 h, the radioactivities of newly synthesized RNA labeled with 14C-UR accumulated in the region of 45S and 32S preribosomal RNA, and no processing to 28S rRNA was observed. Radioactivity corresponding to 3H-5FU did not persist in the preribosomal RNA region, because further maturation proceeded in the condition of depletion of 5FU after the long incubation period. Thus, inhibition of the processing of preribosomal RNA to 28S rRNA was not brought about by the accumulation of 5FU-substituted 45S preribosomal RNA, but by some other, yet unknown, mechanism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698176     DOI: 10.1007/bf00299864

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

Review 1.  EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.

Authors:  C HEIDELBERGER; F J ANSFIELD
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

2.  Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase.

Authors:  K U HARTMANN; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1961-11       Impact factor: 5.157

3.  Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance.

Authors:  C HEIDELBERGER; G KALDOR; K L MUKHERJEE; P B DANNEBERG
Journal:  Cancer Res       Date:  1960-07       Impact factor: 12.701

4.  Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA.

Authors:  C K Carrico; R I Glazer
Journal:  Biochem Biophys Res Commun       Date:  1979-04-13       Impact factor: 3.575

5.  Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program.

Authors:  G E Moore; I D Bross; R Ausmans; S Nadler; R Jones; N Slack; A A Rimm
Journal:  Cancer Chemother Rep       Date:  1968-10

6.  Selective inhibition of ribosomal RNA synthesis in mammalian cells.

Authors:  A Tavitian; S C Uretsky; G Acs
Journal:  Biochim Biophys Acta       Date:  1968-03-18

7.  The effect of 5-fluorouridine 5'-triphosphate on RNA transcribed in isolated nuclei in vitro.

Authors:  R I Glazer; M Legraverend
Journal:  Mol Pharmacol       Date:  1980-03       Impact factor: 4.436

Review 8.  Processing of RNA.

Authors:  R P Perry
Journal:  Annu Rev Biochem       Date:  1976       Impact factor: 23.643

9.  Specific inhibition of transfer RNA methylation and modification in tissues of mice treated with 5-fluorouracil.

Authors:  W C Tseng; D Medina; K Randerath
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

10.  A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.

Authors:  F Ansfield; J Klotz; T Nealon; G Ramirez; J Minton; G Hill; W Wilson; H Davis; G Cornell
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

View more
  14 in total

1.  Scission of the p53-MDM2 Loop by Ribosomal Proteins.

Authors:  Xiang Zhou; Jun-Ming Liao; Wen-Juan Liao; Hua Lu
Journal:  Genes Cancer       Date:  2012-03

Review 2.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

3.  Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.

Authors:  Tiffany S Stolworthy; Aaron M Korkegian; Candice L Willmon; Andressa Ardiani; Jennifer Cundiff; Barry L Stoddard; Margaret E Black
Journal:  J Mol Biol       Date:  2008-01-11       Impact factor: 5.469

5.  Novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21: antitumor activity and effect on humoral immune response in mice.

Authors:  H Mori; K Nakayama; D Maeda; H Nagai; A Koda; J Kita; Y Kaku
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Linking uracil base excision repair and 5-fluorouracil toxicity in yeast.

Authors:  Lauren Seiple; Pawel Jaruga; Miral Dizdaroglu; James T Stivers
Journal:  Nucleic Acids Res       Date:  2006-01-10       Impact factor: 16.971

7.  Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo.

Authors:  Xinliang Zhao; Yi-Tao Yu
Journal:  Nucleic Acids Res       Date:  2006-12-14       Impact factor: 16.971

8.  Fission yeast strains with circular chromosomes require the 9-1-1 checkpoint complex for the viability in response to the anti-cancer drug 5-fluorodeoxyuridine.

Authors:  Hossain Mohammad Shamim; Yukako Minami; Daiki Tanaka; Shinobu Ukimori; Johanne M Murray; Masaru Ueno
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

9.  Kinetic analysis of 5-fluorouracil action against various cancer cells.

Authors:  M Inaba; J Mitsuhashi; S Ozawa
Journal:  Jpn J Cancer Res       Date:  1990-10

10.  Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment.

Authors:  Carolina Negrei; Ariana Hudita; Octav Ginghina; Bianca Galateanu; Sorina Nicoleta Voicu; Miriana Stan; Marieta Costache; Concettina Fenga; Nikolaos Drakoulis; Aristidis M Tsatsakis
Journal:  Front Pharmacol       Date:  2016-06-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.